
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
WebsitePrice
Market cap
Next catalystExpected Q4 2026Ervogastat/resmetirom — planned Phase 2 combination trial · Regulatory meetingSEC filing ↗
Cash
Chart & Events
Core Clinical
PreINDP1P2FilingApproved
PreINDP1P3FilingApproved
Technology Summary
Scientific context
Detailed technology interpretation
Technology advantages
Clinical
Upcoming clinical milestones
PreINDP1P3FilingApproved
PreINDP1P2FilingApproved
Other pipelines
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
PreINDP1P2P3FilingApproved
Approved / commercial
History / paused
MDGL PR & News
PR & News
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.
MADRIGAL PHARMACEUTICALS, INC.